HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Alcoholic hepatitis — Clinical Guidelines

Overview

Alcoholic hepatitis (AH) is a severe liver condition resulting from excessive alcohol consumption, characterized by inflammation and potential liver failure, often preceding cirrhosis 13. It presents with significant morbidity and mortality, influenced by factors such as infection risk and organ dysfunction 1 3 5.

Diagnosis

Elevated liver enzymes (AST, ALT, bilirubin) 1 2.

Prognostic scoring systems like MELD (Model for End-Stage Liver Disease) 2.

Imaging may show signs of portal hypertension 3.

Elevated HVPG (hepatic venous pressure gradient) in severe cases 3.

Consider ADAMTS13 activity and von Willebrand factor levels for prognostic assessment 9 10 11.

Management

First-line treatment: Glucocorticosteroids (e.g., prednisolone) reduce mortality in severe AH 7 (Evidence: Strong).

Adjunctive therapies: Granulocytapheresis (GCAP) explored in small case series 8 (Evidence: Weak).

Infection prophylaxis: Consider due to increased risk, though specific recommendations vary 1 (Evidence: Moderate).

Supportive care: Management of complications like hepatic encephalopathy, coagulopathy, and renal failure 12.

Monitoring: Regular assessment of AKBR (arterial blood ketone body ratio) for prognosis 12 (Evidence: Moderate).

Special Populations

Elderly: Sarcopenia associated with longer hospital stays and multiorgan dysfunction 5 (Evidence: Moderate).

Comorbidities: Presence of renal failure noted in some cases treated with GCAP 8 (Evidence: Weak).

Key Recommendations

Initiate glucocorticosteroids for severe AH to reduce mortality (Evidence: Strong) 7.

Monitor for and manage infections proactively due to high mortality risk (Evidence: Moderate) 1.

Consider ADAMTS13 activity and von Willebrand factor levels for risk stratification in severe cases (Evidence: Weak) 9 10 11.

References

1 Buttler L, Stange J, Pyrsopoulos N, Hassanein T, Wedemeyer H, Maasoumy B et al.. Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality. Liver international : official journal of the International Association for the Study of the Liver 2025. link 2 Idalsoaga F, Díaz LA, Dunn W, Mehta H, Muñoz K, Caldentey V et al.. Moderate alcohol-associated hepatitis: A real-world multicenter study. Hepatology communications 2025. link 3 Jindal A, Sharma MK, Vijayaraghavan R, Sm S, Kumar G, Sarin SK. Severity of Acute Portal Hypertension Determines the Clinical Outcomes in Severe Alcoholic Hepatitis. Digestive diseases and sciences 2024. link 4 Luo J, Zhang J, Lai W, Wang S, Zhou L, Shi Y et al.. Disseminated Human Parvovirus B19 Infection Induced Multiple Organ Dysfunction Syndrome in an Adult Patient With Alcoholic Hepatitis Complicated by Hemolytic Anemia: A Case Report and Literature Review. Frontiers in immunology 2021. link 5 Al-Azzawi Y, Albo B, Fasullo M, Coukos J, Watts GJ, Tai R et al.. Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis. European journal of gastroenterology & hepatology 2020. link 6 Chirapongsathorn S, Kamath PS, Shah V. Alcoholic hepatitis: Can we outwit the Grim Reaper?. Hepatology (Baltimore, Md.) 2015. link 7 Braillon A. Severe alcoholic hepatitis: glucocorticoid saves lives and transplantation is promising. World journal of gastroenterology 2011. link 8 Morris JM, Dickson S, Neilson M, Hodgins P, Forrest EH. Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series. European journal of gastroenterology & hepatology 2010. link 9 Uemura M, Fujimura Y, Matsuyama T, Matsumoto M, Ishikawa M, Ishizashi H et al.. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Current drug abuse reviews 2008. link 10 Matsuyama T, Uemura M, Ishikawa M, Matsumoto M, Ishizashi H, Kato S et al.. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcoholism, clinical and experimental research 2007. link 11 Uemura M, Matsuyama T, Ishikawa M, Fujimoto M, Kojima H, Sakurai S et al.. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcoholism, clinical and experimental research 2005. link 12 Saibara T, Maeda T, Onishi S, Yamamoto Y. The arterial blood ketone body ratio as a possible marker of multi-organ failure in patients with alcoholic hepatitis. Liver 1994. link 13 Sherlock S. Alcoholic hepatitis. Alcohol and alcoholism (Oxford, Oxfordshire) 1990. link

Alcoholic hepatitis